Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis
- 1 June 2008
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 14 (5), 663-670
- https://doi.org/10.1177/1352458507085759
Abstract
Forty relapsing multiple sclerosis patients with 1–15 gadolinium (Gd)-enhancing lesions on screening brain magnetic resonance imaging (MRI) and Expanded Disability Status Scale (EDSS) scores 0–6.5 were randomized to receive short-term induction therapy with mitoxantrone (three monthly 12 mg/m2 infusions) followed by 12 months of daily glatiramer acetate (GA) therapy 20 mg/day subcutaneously for a total of 15 months (M-GA, n = 21) or daily GA 20 mg/day for 15 months (GA, n = 19). MRI scans were performed at months 6, 9, 12 and 15. The primary measure of outcome was the incidence of adverse events; secondary measures included number of Gd-enhanced lesions, confirmed relapses and EDSS changes. Except age, baseline demographic characteristics were well matched in both treatment arms. Both treatments were safe and well tolerated. M-GA induction produced an 89% greater reduction (relative risk (RR) = 0.11, 95% confidence interval (CI): 0.04–0.36, p = 0.0001) in the number of Gd-enhancing lesions at months 6 and 9 and a 70% reduction (RR = 0.30, 95% CI: 0.11–0.86, p = 0.0147) at months 12 and 15 versus GA alone. Mean relapse rates were 0.16 and 0.32 in the M-GA and GA groups, respectively. Short-term immunosuppression with mitoxantrone followed by daily GA for up to 15 months was found to be safe and effective, with an early and sustained decrease in MRI disease activity.Keywords
This publication has 25 references indexed in Scilit:
- Evidence for neuroprotection and remyelination using imaging techniquesNeurology, 2007
- Natalizumab plus Interferon Beta-1a for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006
- The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis miceProceedings of the National Academy of Sciences, 2005
- Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivoBrain, 2004
- Glatiramer acetate for the treatment of multiple sclerosisExpert Opinion on Pharmacotherapy, 2004
- Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MSMultiple Sclerosis Journal, 2001
- European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosisAnnals of Neurology, 2001
- Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcomeZeitschrift für Neurologie, 1997
- Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.Journal of Neurology, Neurosurgery & Psychiatry, 1997
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995